(Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-09818 ALLIANCEBERNSTEIN HOLDING L.P. (Exact name of registrant as specified in its charter) Delaware 13-3434400 (State or other jurisdi ...

NASHVILLE, Tenn., July 22, 2025 /PRNewswire/ -- AllianceBernstein L.P. ("AB") (NYSE: AB), a leading global investment management firm, announced today it has added Pacific Life to back its multi-insurer platform delivering lifetime income solutions to large Defined Contribution (DC) plans.Today's announcement with Pacific Life is the latest in the global asset management firm's continued expansion of its retirement income capabilities. AB's lifetime income platform consists of the Lifetime Income Strategy ( ...

Group 1 - The Chinese capital market is experiencing a new pattern of deep interaction with foreign institutions, enhancing the convenience for global investors to participate in China's innovative development opportunities [1] - International capital's enthusiasm for allocating assets in China is increasing, with many foreign institutions expressing optimism about the Chinese market's prospects [1][2] - A significant shift has occurred in the priorities of sovereign wealth funds, with 59% of respondents identifying China as a high or medium priority market, indicating a separate allocation to China from broader emerging markets [2] Group 2 - The quality of listed companies in China is improving, providing a solid foundation for foreign institutions' interest, with 60% of companies reporting positive revenue growth in 2024 [3] - Foreign institutions are increasingly focusing on technology innovation, with digital technology and software being the most attractive investment areas, followed by advanced manufacturing and clean energy [5] - The bond market is also attracting international capital, with expectations that capital may flow from the US financial markets to other fixed-income markets, benefiting European, Japanese, and Chinese bonds [5] Group 3 - Foreign institutions are accelerating their investment in the Chinese market, with over 30 new funds launched by firms such as Morgan Asset Management and Fidelity [6] - Several foreign institutions are demonstrating long-term commitment to the Chinese market through capital increases, such as Morgan Stanley Fund's registered capital rising from 600 million to 950 million yuan, a growth of over 58% [6]

Here are three stocks with buy rank and strong income characteristics for investors to consider today, July 14th:Wipro Limited (WIT) : This information technology, consulting, and business process services company has witnessed the Zacks Consensus Estimate for its current year earnings increasing 7.1% over the last 60 days.This Zacks Rank #1 company has a dividend yield of 2.1%, compared with the industry average of 0.0%.AllianceBernstein Holding L.P. (AB) : This publicly owned investment management company ...

Core Viewpoint - Investors in the Financial - Investment Management sector should consider AllianceBernstein (AB) and Cohen & Steers Inc (CNS) for potential value opportunities [1] Valuation Metrics - AllianceBernstein has a forward P/E ratio of 12.76, while Cohen & Steers has a forward P/E of 25.95 [5] - The PEG ratio for AB is 1.64, indicating a more favorable earnings growth outlook compared to CNS's PEG ratio of 2.55 [5] - AB's P/B ratio is 2.31, significantly lower than CNS's P/B ratio of 7.61, suggesting AB is more undervalued relative to its book value [6] Investment Rankings - AllianceBernstein holds a Zacks Rank of 2 (Buy), indicating a positive earnings outlook, while Cohen & Steers has a Zacks Rank of 3 (Hold) [3] - The stronger estimate revision activity for AB, along with its more attractive valuation metrics, positions it as the superior investment option compared to CNS [7]

Core Insights - AllianceBernstein L.P. and AllianceBernstein Holding L.P. reported a preliminary increase in assets under management (AUM) to $829 billion in June 2025, up from $803 billion at the end of May, representing a 3% month-over-month growth driven by market appreciation and modest net inflows [1][2] - The firm experienced net outflows totaling $6.7 billion for the quarter ending June 2025, with institutional net inflows being partially offset by net outflows from retail and private wealth segments during June [1][2] AUM Breakdown - As of June 30, 2025, the total AUM was composed of: - Total Equity: $344 billion, up from $332 billion in May, with actively managed equity at $273 billion and passive equity at $71 billion [2] - Total Fixed Income: $304 billion, an increase from $295 billion in May, with taxable fixed income at $215 billion and tax-exempt fixed income at $79 billion [2] - Alternatives/Multi-Asset: $181 billion, up from $176 billion in May [2] - The AUM for private wealth was $144 billion, reflecting a slight increase from $140 billion in May [2] Company Overview - AllianceBernstein is recognized as a leading global investment management firm, providing diversified investment services to institutional investors, individuals, and private wealth clients across major world markets [5][6] - As of June 30, 2025, AllianceBernstein Holding owned approximately 37.5% of AllianceBernstein, while Equitable Holdings, Inc. owned an approximate 68.6% economic interest in the firm [6]

Group 1 - Bernstein Private Wealth Management is expanding its ultrahigh-net-worth (UHNW) services through inorganic growth strategies, including targeted recruiting and selective acquisitions of registered investment advisors (RIAs) [2][3] - The firm has appointed three new leaders: Craig Storch as Senior Managing Director for Growth Strategies, Neel Ray as Senior National Director, and Marshall Butler as Head of Marketing, all reporting to Aaron Bates [2][3][5] - Bernstein's UHNW segment is experiencing notable momentum, and the firm aims to leverage its global asset management resources to enhance advisor practices and client outcomes [3][4] Group 2 - The new hires and acquisitions will be based on cultural fit and fiduciary mindset, aligning with Bernstein's long-standing commitment to organic talent development [3][4] - Bernstein continues to introduce tailored solutions for UHNW clients, including family offices, and has opened a new office in Hudson Yards, New York City [6] - As of May 31, 2025, AllianceBernstein manages $803 billion in assets, positioning Bernstein among the largest investment managers globally [7]

Core Viewpoint - AB Science S.A. successfully completed a private placement raising EUR 1.925 million to finance ongoing activities, particularly the clinical development of the AB8939 program [1][3]. Use of Proceeds - The net proceeds from the private placement will be utilized to support the clinical development of the AB8939 program and strengthen the company's cash position to meet financing needs for 2025 and beyond [3]. Private Placement Details - The private placement involved the issuance of 1,645,302 new ordinary shares, each with an attached share warrant (BSA), without preferential subscription rights [4][5]. - The issue price of one ABSA is EUR 1.17, reflecting a 24.36% discount to the volume-weighted average price (VWAP) of AB Science shares over the three trading days prior to the pricing [6][7]. Shareholder Impact - Post-placement, the new shares will represent approximately 2.47% of the company's share capital on a non-diluted basis before the placement and 2.41% after [5]. - Existing shareholders who do not participate in the private placement will experience a dilution of their shareholding [12][22]. Trading and Admission - The new shares are expected to be admitted to trading on Euronext Paris on July 10, 2025, and will be assimilated to existing shares [13]. Lock-up Commitments - The company has agreed to a 45-day lock-up period for the investors and a 90-day lock-up for its directors and officers following the settlement and delivery of the private placement [17].

Core Viewpoint - The FDA and EMA have authorized a confirmatory Phase 3 trial for masitinib in metastatic castrate-resistant prostate cancer (mCRPC), utilizing a biomarker-driven patient selection approach to target those most likely to benefit from the treatment [1][2]. Study Design - Study AB22007 is a multicenter, randomized, double-blind, placebo-controlled Phase 3 trial designed to confirm the efficacy and safety of masitinib in combination with docetaxel for mCRPC patients [3]. - The trial will enroll 600 patients, with a primary endpoint of radiographic progression-free survival (rPFS) and overall survival as the first secondary endpoint [4]. Medical Need - Masitinib is positioned to address a high unmet medical need in mCRPC patients who have relapsed after hormone treatments, as there are currently no registered drugs for use in combination with docetaxel in this patient population [5][6]. - Metastatic prostate cancer has a 5-year survival rate of approximately 30%, highlighting the critical need for effective treatments [7]. Patient Population - The estimated population of mCRPC patients eligible for chemotherapy is around 75,000 in the EU and 50,000 in the USA [8]. - The biomarker alkaline phosphatase (ALP) has been validated to predict the response to masitinib in mCRPC patients, indicating a potential new first-line treatment option [8]. Efficacy Results - The combination of masitinib and docetaxel showed a significant progression-free survival (PFS) benefit, with a hazard ratio of 0.79, indicating a 21% reduction in the risk of progression compared to control [10]. - A greater treatment effect was observed in patients with lower baseline ALP levels, with a 47% reduced risk of progression in those with ALP ≤ 100 IU/L [11]. Safety Profile - The safety profile of masitinib in combination with docetaxel was acceptable, with no new safety signals observed, marking a successful example of a Phase 3 trial that improved PFS [13]. Patent Protection - AB Science has filed a patent application for methods of treating mCRPC with masitinib, which has been granted by the European Patent Office, providing protection until 2042 for the treatment of mCRPC in patients with low metastatic involvement [14][15].

Core Viewpoint - AllianceBernstein L.P. and AllianceBernstein Holding L.P. will release their Second Quarter 2025 financial and operating results on July 24, 2025, before market opening [1] Group 1: Financial Results Announcement - The financial results will be discussed in a teleconference starting at 9:00 am (CT) on July 24, 2025, hosted by key executives including the President and CEO, CFO, and Head of Global Client Group and Private Wealth [1] - The presentation for the conference call will be available on the Investor Relations website shortly after the results are released [2] - A replay of the webcast will be accessible approximately one hour after the conference call concludes on the same day [2] Group 2: Company Overview - AllianceBernstein is recognized as a leading global investment management firm, providing diversified investment services to institutional investors, individuals, and private wealth clients across major world markets [3] - As of March 31, 2025, AllianceBernstein Holding owned approximately 37.5% of AllianceBernstein, while Equitable Holdings, Inc. owned about 61.9% economic interest in the firm [4]